In addition, blocking of VEGF pathway by bevacizumab or vandetanib has been demonstrated to be effective against mouse xenograft model harboring an EGFR T790M mutation [21,22] and a high effectiveness of erlotinib plus bevacizumab was also observed in EGFR-mutated NSCLC patients presenting a de novo T790M [23]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.